


We claim:

1. A tetrahydrobenzazepine of the general formula I

5



in which

A is a single bond or CH_2 ;

10

B is a single bond or a group NR^3 ;

15

Y is a single bond, CH_2 or a group NR^3 , where A, B and Y are not simultaneously a single bond;

20

Ar is an aromatic radical which is selected from phenyl and a 5- or 6-membered heteroaromatic radical having 1, 2, 3 or 4 heteroatoms which are selected independently of one another from O, N and S, where the aromatic radical may have 1, 2 or 3 substituents which are selected independently of one another from $\text{C}_1\text{-C}_6$ -alkyl which is optionally substituted one or more times by OH, $\text{C}_1\text{-C}_4$ -alkoxy, halogen or phenyl, or $\text{C}_2\text{-C}_6$ -alkenyl which is optionally substituted one or more times by OH, $\text{C}_1\text{-C}_4$ -alkoxy, halogen or phenyl, or $\text{C}_2\text{-C}_6$ -alkynyl which is optionally substituted one or more times by OH, $\text{C}_1\text{-C}_4$ -alkoxy, halogen or phenyl, or $\text{C}_3\text{-C}_6$ -cycloalkyl which is optionally substituted one or more times by OH, $\text{C}_1\text{-C}_4$ -alkoxy, halogen, phenyl or $\text{C}_1\text{-C}_4$ -alkyl, or halogen, CN, OR^4 , COOR^4 , NR^5R^6 , CONR^5R^6 , NO_2 , SR^7 , SO_2R^7 , $\text{SO}_2\text{NR}^5\text{R}^6$, COR^8 , and phenyl which optionally has one, two or three substituents which are selected independently of one another from $\text{C}_1\text{-C}_4$ -alkyl, $\text{C}_1\text{-C}_4$ -alkoxy, NR^5R^6 , CN, $\text{C}_1\text{-C}_2$ -fluoroalkyl or halogen, where phenyl and the heterocyclic radical may also be fused to a 5- or 6-membered aromatic or nonaromatic carbocycle, or phenyl may be fused to a 5- or 6-membered aromatic or nonaromatic heterocycle which has 1, 2 or 3 heteroatoms selected from O, N and S;

25

R^1 is hydrogen, $\text{C}_1\text{-C}_8$ -alkyl, $\text{C}_1\text{-C}_8$ -haloalkyl, $\text{C}_2\text{-C}_8$ -alkenyl, $\text{C}_2\text{-C}_8$ -haloalkenyl, $\text{C}_2\text{-C}_8$ -alkynyl, $\text{C}_2\text{-C}_8$ -haloalkynyl, $\text{C}_1\text{-C}_8$ -alkylcarbonyl, $\text{C}_1\text{-C}_8$ -haloalkylcarbonyl or substituted $\text{C}_1\text{-C}_8$ -alkyl which carries a substituent which is selected from OH, $\text{C}_1\text{-C}_4$ -alkoxy, $\text{C}_1\text{-C}_4$ -alkylamino, Di-($\text{C}_1\text{-C}_4$ -alkyl)amino, phenyl, phenoxy, $\text{C}_3\text{-C}_8$ -cycloalkyl and $\text{C}_3\text{-C}_8$ -cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from OH, CN, NO_2 , $\text{C}_1\text{-C}_4$ -alkyl,

30

35

C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy and halogen;

5 R² is hydrogen, halogen, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkyl, C₁-C₄-haloalkoxy, OH, NO₂, CN, COOR⁴, NR⁵R⁶ or CONR⁵R⁶;

10 R³ is hydrogen, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkylcarbonyl, phenyl, phenyl-C₁-C₄-alkyl or phenylcarbonyl, where phenyl in the last three radicals mentioned may optionally have 1, 2 or 3 substituents which are selected independently of one another from C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and halogen;

15 R⁴ to R⁸ are independently of one another H, C₁-C₆-alkyl which may carry a substituent selected from OH, C₁-C₄-alkoxy and optionally substituted phenyl, C₁-C₆-haloalkyl or phenyl, where R⁶ may also be a group COR⁹ in which R⁹ is H, C₁-C₆-alkyl which is optionally substituted by OH, C₁-C₄-alkoxy or optionally substituted phenyl, or C₁-C₆-haloalkyl or phenyl, where

20 R⁵ with R⁶ may also together with the nitrogen atom to which they are bonded be a 5- or 6-membered saturated or unsaturated N-heterocycle which may optionally have a further heteroatom selected from O, S and NR¹⁰ as ring member, where R¹⁰ is hydrogen or C₁-C₄-alkyl;

the N-oxides of this compound, the physiologically tolerated acid addition salts of this compound and the physiologically tolerated acid addition salts of the N-oxides of I.

25 2. A tetrahydrobenzazepine of the general formula I as claimed in claim 1, in which A and Y are a single bond, and B is a group NR³.

3. A tetrahydrobenzazepine of the general formula I as claimed in claim 1, in which A and B together are a single bond, and Y is a group NR³.

30 4. A tetrahydrobenzazepine of the general formula I as claimed in claim 1, in which A is CH₂, and B and Y are each a single bond.

5. A tetrahydrobenzazepine of the general formula I as claimed in claim 1, in which Y is CH₂, and A and B together are a single bond.


35 6. A tetrahydrobenzazepine of the general formula I as claimed in any of the preceding claims, in which R² is hydrogen.

40 7. A tetrahydrobenzazepine of the general formula I as claimed in any of the preceding claims, in which Ar is phenyl which may be substituted in the abovementioned manner.

8. A tetrahydrobenzazepine of the general formula I as claimed in claim 7, in which phenyl is unsubstituted or has 1 or 2 substituents, of which one substituent is arranged in the para position relative to the variable Y.

5 9. A tetrahydrobenzazepine of the general formula I as claimed in claim 7 or 8, in which the substituents on the phenyl are selected from C₂-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl and C₁-C₂-fluoroalkyl.

10. A compound as claimed in claim 1, wherein Ar is phenyl which carries a radical R^P which is located in the para position of the phenyl ring wherein R^P has the following formula R^P:



wherein

Y is N, CH or CF,

15 R^{a1} and R^{a2} are independently of each other selected from C₁-C₂-alkyl, fluorinated C₁-C₂-alkyl, provided for Y being CH or CF one of the radicals R^{a1} or R^{a2} may also be hydrogen or fluorine, or


R^{a1} and R^{a2} form a radical (CH₂)_m wherein 1 or 2 of the hydrogen atoms may be replaced by fluorine and wherein m is 2, 3 or 4.

20 11. A tetrahydrobenzazepine of the general formula I as claimed in any of claims 1 to 6, in which Ar is a 5- or 6-membered heteroaromatic radical having 1, 2, 3 or 4 heteroatoms which are selected independently of one another from O, N and S, where the heteroaromatic radical may be substituted in the abovementioned manner.

25 12. A tetrahydrobenzazepine of the general formula I as claimed in any of the preceding claims, in which R¹ has the general formula CH₂-R^{1a} in which R^{1a} is C₁-C₇-alkyl, C₁-C₇-haloalkyl, C₂-C₇-alkenyl, C₂-C₇-haloalkenyl, C₂-C₇-alkynyl, C₂-C₇-haloalkynyl or C₁-C₇-alkyl which has a substituent which is selected from OH, C₁-C₄-alkoxy, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, phenyl, phenoxy, C₃-C₈-cycloalkyl and C₃-C₈-cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and halogen, or C₁-C₄-alkoxy, C₁-C₄-alkylamino, di-C₁-C₄-alkylamino, phenyl, phenoxy, C₃-C₈-cycloalkyl or C₃-C₈-cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy and halogen.

30 35 40 13. A tetrahydrobenzazepine of the general formula I as claimed in claim 11, in which R^{1a} is C₁-C₇-alkyl, C₂-C₇-alkenyl, C₂-C₇-alkynyl, C₃-C₈-cycloalkyl or C₁-C₇-fluoroalkyl.

14. A tetrahydrobenzazepine as claimed in claim 12 of the general formula I.A/B



5 in which


Q is CH_2 or NR^3 ,

10 R^1 is a group $\text{CH}_2-\text{R}^{1a}$ in which R^{1a} has the meanings indicated in claim 11, and

R^P is $\text{C}_2\text{-C}_6$ -alkyl, $\text{C}_2\text{-C}_6$ -alkenyl, $\text{C}_2\text{-C}_6$ -alkynyl or $\text{C}_1\text{-C}_4$ -fluoroalkyl.

15. 15. A tetrahydrobenzazepine as claimed in claim 14, in which R^{1a} is selected from methyl, ethyl, fluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, cyclopropyl or vinyl and R^P is selected from ethyl, vinyl, isopropyl, tert-butyl and trifluoromethyl.

20 16. A tetrahydrobenzazepine as claimed in claim 14, wherein R^P is selected from a radical of the formula



20

wherein

Y is N, CH or CF,

25 R^{a1} and R^{a2} are independently of each other selected from $\text{C}_1\text{-C}_2$ -alkyl, fluorinated $\text{C}_1\text{-C}_2$ -alkyl, provided for Y being CH or CF one of the radicals R^{a1} or R^{a2} may also be hydrogen or fluorine, or

30 R^{a1} and R^{a2} form a radical $(\text{CH}_2)_m$ wherein 1 or 2 of the hydrogen atoms may be replaced by fluorine and wherein m is 2, 3 or 4; and R^{1a} is ethyl.

35 17. A tetrahydrobenzazepine as claimed in claim 16, wherein R^P is selected from isopropyl, (R)-1-fluoroethyl, (S)-1-fluoroethyl, 2-fluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, (R)-1-fluoropropyl, (S)-1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1,1-difluoropropyl, 2,2-difluoropropyl, 3,3-difluoropropyl, 3,3,3-trifluoropropyl, (R)-2-fluoro-1-methylethyl, (S)-2-fluoro-1-methylethyl, (R)-2,2-difluoro-1-methylethyl, (S)-2,2-difluoro-1-methylethyl, (R)-1,2-difluoro-1-methylethyl, (S)-1,2-difluoro-1-methylethyl, (R)-2,2,2-trifluoro-1-methylethyl, (S)-2,2,2-trifluoro-1-methylethyl, 2-fluoro-1-(fluoromethyl)ethyl, 1-(difluoromethyl)-2,2-difluoroethyl, 1-fluoro-1-methylethyl, cyclopropyl, cyclobutyl,

1-fluorocyclopropyl, 2,2-difluorocyclopropyl and 2-fluorocyclopropyl.

18. A pharmaceutical composition comprising at least one active ingredient selected from compound of the general formula I as claimed in any of claims 1 to 17, the physiologically

5 tolerated acid addition salts of I, the N-oxides of compounds of the general formula I, and the physiologically tolerated acid addition salts of the N-oxides of I, where appropriate together with physiologically acceptable carriers and/or excipients.

19. The use of at least one compound of the general formula I as claimed in any of claims 1

10 to 15, its acid addition salts, its N-oxides and the acid addition salts of the N-oxides for producing a pharmaceutical composition for the treatment of disorders which respond to the influence of dopamine D₃ receptor antagonists or agonists.

20. The use as claimed in claim 19 for the treatment of disorders of the central nervous

15 system.

21. The use as claimed in claim 19 for the treatment of renal function disorders.

22. A method for treating a medical disorder susceptible to treatment with a dopamine D3

20 receptor ligand, said method comprising administering an effective amount of at least one compound as claimed in claim 1 to a subject in need thereof.

23. The method as claimed in claim 22, wherein the medical disorder is a disease of the central nervous system.